DDInter1008 DDInter32
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue
Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test . Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim .
Ketoconazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Afatinib
Ketoconazole {u} (Compound) upregulates {v} (Gene) ACAT2
ACAT2 {u} (Gene) is upregulated by {v} (Compound) Afatinib
Ketoconazole {u} (Compound) downregulates {v} (Gene) SLC35F2
SLC35F2 {u} (Gene) is downregulated by {v} (Compound) Afatinib
Ketoconazole {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Afatinib
Ketoconazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Gefitinib
Gefitinib {u} (Compound) resembles {v} (Compound) Afatinib
Ketoconazole {u} (Compound) upregulates {v} (Gene) ACAT2
ACAT2 {u} (Gene) is regulated by {v} (Gene) EPHA6
EPHA6 {u} (Gene) is bound by {v} (Compound) Afatinib
Ketoconazole {u} (Compound) upregulates {v} (Gene) INSIG1
INSIG1 {u} (Gene) regulates {v} (Gene) CNOT4
CNOT4 {u} (Gene) is upregulated by {v} (Compound) Afatinib
Ketoconazole {u} (Compound) upregulates {v} (Gene) FDFT1
FDFT1 {u} (Gene) regulates {v} (Gene) PHKG2
PHKG2 {u} (Gene) is bound by {v} (Compound) Afatinib
Ketoconazole {u} (Compound) upregulates {v} (Gene) ABHD4
ABHD4 {u} (Gene) is upregulated by {v} (Compound) Gefitinib
Gefitinib {u} (Compound) resembles {v} (Compound) Afatinib
Ketoconazole {u} (Compound) downregulates {v} (Gene) SLC35F2
SLC35F2 {u} (Gene) is downregulated by {v} (Compound) Gefitinib
Gefitinib {u} (Compound) resembles {v} (Compound) Afatinib
Ketoconazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Afatinib (Compound)
Ketoconazole (Compound) upregulates ACAT2 (Gene) and ACAT2 (Gene) is upregulated by Afatinib (Compound)
Ketoconazole (Compound) downregulates SLC35F2 (Gene) and SLC35F2 (Gene) is downregulated by Afatinib (Compound)
Ketoconazole (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Afatinib (Compound)
Ketoconazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Gefitinib (Compound) and Gefitinib (Compound) resembles Afatinib (Compound)
Ketoconazole (Compound) upregulates ACAT2 (Gene) and ACAT2 (Gene) is regulated by EPHA6 (Gene) and EPHA6 (Gene) is bound by Afatinib (Compound)
Ketoconazole (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) regulates CNOT4 (Gene) and CNOT4 (Gene) is upregulated by Afatinib (Compound)
Ketoconazole (Compound) upregulates FDFT1 (Gene) and FDFT1 (Gene) regulates PHKG2 (Gene) and PHKG2 (Gene) is bound by Afatinib (Compound)
Ketoconazole (Compound) upregulates ABHD4 (Gene) and ABHD4 (Gene) is upregulated by Gefitinib (Compound) and Gefitinib (Compound) resembles Afatinib (Compound)
Ketoconazole (Compound) downregulates SLC35F2 (Gene) and SLC35F2 (Gene) is downregulated by Gefitinib (Compound) and Gefitinib (Compound) resembles Afatinib (Compound)